Biodesix expects $101M-$103M 2026 revenue while planning to exit 2026 with ~115 sales reps (NASDAQ:BDSX)
Biodesix reported 10% revenue growth in Q3 2026, with diagnostic testing revenue up 16% and test volumes increasing 24%. The company maintains a gross margin of 81%. Management expects 2026 revenue to be $101M-$103M and plans to have around 115 sales reps by year-end, according to CEO Scott Hutton.
How this was made
The 30-second read
Why it matters
Earnings beat may trigger short‑term price rally and attract new institutional interest.
Market read
First‑time disclosure of Q3 performance provides fresh data for traders.
What to watch
Potential regulatory or reimbursement risks not addressed in the call.
Background
Biodesix is a molecular diagnostics company focused on lung disease testing.
Ticker impact
Biodesix reported Q3 revenue up 10% and diagnostic testing revenue up 16% with gross margin at 81% during its earnings call.
likely upward pressure as investors price in better‑than‑expected growth
Revenue and margin beats signal improved demand for diagnostics, supporting a bullish bias.
Market effects
Positive earnings may lift other diagnostic and biotech peers.
Limited to US biotech sector.
Modest; primarily affects niche diagnostic market.
Counterpoint
If growth slows in upcoming quarters, current optimism could be premature.
Key entities
- ExecutiveScott Hutton
President, CEO & Director of Biodesix who delivered the earnings commentary.


